663P Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC
Carlos Rojas, Iwona Ługowska, Rosalyn A. Juergens, Adrian G. Sacher, Susanne Weindler, Mehmet Alı Nahıt Şendur, Rafał Dziadziuszko, Abhijit Pal, Eduardo Castañón Álvarez, E.S. Ahern, Nehal J. Lakhani, Li‐Chia Chen, Thomas Jemielita, Yoonyoung Choi, Anastasios Stathis
Topics & Concepts
MedicineResponse Evaluation Criteria in Solid TumorsPembrolizumabKRASClinical endpointInternal medicineToxicityOncologySurgeryPhases of clinical researchNuclear medicineCancerClinical trialColorectal cancerImmunotherapyColorectal Cancer Treatments and StudiesLung Cancer Treatments and MutationsBiochemical and Molecular Research